# Engineered Immune Cells Eradicate Aggressive Brain Tumors in Mouse Models A new targeted CAR-T therapy activates only within the brain to destroy lethal gliomas. - **Source:** [ScienceDaily – Mind & Brain](https://www.sciencedaily.com/news/mind_brain) - **Published:** 2026-11-08 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/639d414e-b90a-4343-a11b-969b1366f78b ## Targeted Brain Cancer Therapy Scientists at UC San Francisco developed a novel immune cell therapy, B-SYNC CAR-T, designed to treat aggressive brain cancers like diffuse midline glioma. Unlike traditional treatments, these engineered cells remain inactive in the bloodstream, only triggering their cancer-fighting mechanisms upon entering the brain environment, which minimizes potential systemic side effects. ## Overcoming Treatment Resistance Conventional CAR-T therapies often struggle with brain tumors due to poor targeting and T cell exhaustion. By utilizing a molecular sensing system called synNotch, the researchers programmed cells to detect brevican, a protein abundant in the brain. This allows the therapy to identify and attack tumor cells with high precision. ## Total Tumor Elimination In experiments involving mice with human diffuse midline glioma, the B-SYNC therapy achieved complete tumor elimination. Researchers administered the cells intravenously and via direct injection into the brain's ventricles. The direct administration proved particularly effective, successfully clearing the aggressive cancer in every single mouse tested during the laboratory study. ## Long-Term Immune Protection The therapy demonstrated lasting efficacy beyond the initial destruction of tumors. When researchers introduced new cancer cells seven weeks later, the treated mice rejected the tumors entirely. Observations confirmed that the engineered immune cells remained functional and continued patrolling for cancer cells for more than 70 days post-treatment in the subjects. ## Mechanism of Action The B-SYNC system relies on a two-step activation process. Once the synNotch sensor detects brevican, the immune cells produce CAR receptors that target EphA2 and IL13R 2 proteins. This design bypasses the need for specific tumor mutations, making the therapy potentially applicable to a broader range of patients than previous experimental models. ## Preventing T Cell Exhaustion Researchers believe the localized activation strategy helps prevent T cell exhaustion, a common failure point in immunotherapy. By keeping the cells dormant until they reach the brain, the therapy preserves their potency for when they encounter tumor cells. This sustained activity is a critical factor in the treatment's observed success. ## Clinical Trial Preparations Following the successful preclinical results published in Science Translational Medicine, the UCSF team is preparing for human clinical trials. These trials, potentially starting as early as April 2027, will evaluate delivery methods including direct administration into the brain. Surgeons plan to use specialized shunts to allow for repeated dosing in patients. ## Clinical Significance and Outlook Diffuse midline glioma remains one of the most lethal childhood cancers, with most patients surviving less than a year. The ability to cure this disease in mouse models offers significant hope for future pediatric treatments. Clinical specialists are now focused on translating these laboratory findings into safe, effective therapies for human patients. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/11/261104084009.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._